ArriVent BioPharma, Inc. Common Stock
HealthcareNASDAQ:AVBP · NASDAQ Global Market
+$0.34 today
Vol 0.43M · Avg 0.49M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-54.1%
avg -55.5%
ROIC
-57.8%
avg -37.2%
ROA
-49.9%
avg -52.4%
Analysis
ROA is currently the strongest return metric at -49.9% versus its period average of -52.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Zhengbin Yao | Co-Founder, Chairman, President & Chief Executive Officer | $968,667.00 | — | 60 | $550,000.00 | 1.18% |
Stuart Lutzker | Co-Founder, President of Research & Development and Director | $777,353.00 | — | 65 | $150,000.00 | 0.32% |
Winston Kung | Chief Financial Officer & Treasurer | $752,704.00 | — | 50 | $140,000.00 | 0.30% |
Robin LaChapelle | Co-Founder & Chief Operating Officer | $586,453.00 | — | 53 | $130,000.00 | 0.28% |
James Paul Kastenmayer | General Counsel & Secretary | — | — | 54 | $130,000.00 | 0.28% |
Brent S. Rice | Chief Commercial Officer | — | — | 60 | — | — |
Yang Wang | Chief Technology Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$12.98M
Net Sentiment
$12.98M
Net selling
Most Active
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Dec 10, 2025 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. Indirect | Sell | 555.6K | $23.37 | $12,983,320.35 |
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $12.98M over the last 12 months. That adds up to net selling of $12.98M. HILLHOUSE INVESTMENT MANAGEMENT, LTD. was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Who manages AVBP?
ArriVent BioPharma, Inc. Common Stock (AVBP) lists 7 active executives. The top listed executive is James Paul Kastenmayer, General Counsel & Secretary.
Are AVBP insiders buying or selling?
Recent insider activity shows net buying of $38.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.